End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
30.08 NZD | -0.63% |
|
-0.69% | +27.46% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- The company is in a robust financial situation considering its net cash and margin position.
- Sales forecast by analysts have been recently revised upwards.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The opinion of analysts covering the stock has improved over the past four months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 51.73 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+27.46% | 10.7B | B+ | ||
-5.60% | 181B | C+ | ||
-4.45% | 101B | C | ||
-4.15% | 67.54B | A | ||
-8.63% | 45.09B | B- | ||
+9.70% | 44.37B | B- | ||
+6.13% | 40.7B | B+ | ||
+15.22% | 29.85B | B | ||
+14.80% | 24.49B | A- | ||
-6.46% | 23.99B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- FPH Stock
- Ratings Fisher & Paykel Healthcare Corporation Limited